Payment overview · 2025
General Payments
$40,219.41
69 reported records · 9 companies
Healthcare provider profile · identity verified
Sanjaya Kumar Gupta, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · KANSAS CITY, MO · NPI 1700904182
Verified facts
What the public records show
CMS Open Payments records show Sanjaya Kumar Gupta, MD received $40,219.41 in general payments during 2025 across 69 reported records.
Boston Scientific Corporation accounted for 61.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24,553.45 | 61.0% | 31 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $5,884.61 | 14.6% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $5,763.94 | 14.3% | 13 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $1,733.04 | 4.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,547.60 | 3.9% | 10 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $382.11 | 0.9% | 3 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $315.45 | 0.8% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $20.24 | 0.1% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $18.97 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,375.00 | 9 |
| Travel and Lodging | $4,807.62 | 13 |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,724.00 | 3 |
| Food and Beverage | $4,037.79 | 41 |
| Consulting Fee | $3,275.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $11,726.98 | 10 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $8,560.17 | 9 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $5,817.82 | 5 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $4,025.00 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $3,967.46 | 6 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $1,733.04 | 2 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $1,150.00 | 1 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $315.45 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $260.91 | 5 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $180.69 | 5 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $166.39 | 2 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| QDOT MICRO Normalized: qdot micro |
Device | Biosense Webster, Inc. | $138.10 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $128.59 | 2 | 2025 |
Source payment records
|
|||||
| EPSILA EV Normalized: epsila ev |
Device | Medtronic, Inc. | $128.19 | 1 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $100.42 | 2 | 2025 |
Source payment records
|
|||||
| Soundstar Normalized: soundstar |
Device | Biosense Webster, Inc. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $37.93 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 509 | 150 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 66 |
| Carvedilol | Carvedilol | 170 | 50 |
| Flecainide Acetate | Flecainide Acetate | 159 | 60 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 154 | 59 |
| Furosemide | Furosemide | 134 | 48 |
| Dofetilide | Dofetilide | 127 | 43 |
| Xarelto | Rivaroxaban | 108 | 33 |
| Lisinopril | Lisinopril | 105 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 30 |
| Spironolactone | Spironolactone | 88 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 84 | 36 |
| Losartan Potassium | Losartan Potassium | 75 | 31 |
| Warfarin Sodium | Warfarin Sodium | 70 | 19 |
| Potassium Chloride | Potassium Chloride | 62 | 23 |
| Sotalol | Sotalol Hcl | 58 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 12 |
| Entresto | Sacubitril/Valsartan | 35 | 11 |
| Jardiance | Empagliflozin | 33 | 13 |
| Ezetimibe | Ezetimibe | 30 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 16 |
| Digoxin | Digoxin | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40,219.41 · 69 records | Boston Scientific Corporation | AFFERA MAPPING SYSTEM, AVEIR, BodyGuardian, CARDIVA VASCADE MVP XL VVCS 10-12F, ENSITE, ENSITE PRECISION, EPSILA EV, FARAPULSE, General - Therapies, Indigo System, MYNX CONTROL VENOUS, NUVISION ICE CATHETER, PERCLOSE PROGLIDE, PERCLOSE PROSTYLE, QDOT MICRO, Sotalol Hydrochloride, Soundstar, WATCHMAN Access System, WATCHMAN FLX, remede System | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error